Skip to Content
Colorado Attorney General

Phil Weiser

Colorado Attorney General

File A Complaint
  • About Us
    • Attorney General Bio & Photos
    • Vision & Values
    • Senior Staff & Organization
    • Colorado Attorney General Annual Report
    • Attorney General Opinions
    • Contact Our Office
  • Sections
    • Administration
    • Business & Licensing
    • Civil Litigation & Employment Law
    • Consumer Protection
    • Criminal Appeals
    • Criminal Justice
    • Natural Resources & Environment
    • Office of Community Engagement
    • Revenue & Utilities
    • State Services
  • Careers
    • Attorney & Other Non-Classified Positions
    • Fellowships
    • Internships
    • Classified Staff Positions
    • Other Opportunities to Join our Team
  • Media Center
    • Press Room
    • Colorado Open Records Act – CORA
  • Resources
    • Survivors of Childhood Sexual Abuse
    • Victim Assistance
    • Budget & Accounting
    • Code of Colorado Regulations
    • Colorado Revised Statutes
    • Coronavirus Information
    • Data Protection Laws
    • Transparency Online Project (TOPS)
  • Licensing
    • Business Resources
    • Collection Agencies & Debt Collectors
    • Colorado Uniform Consumer Credit Code: Licensing & Notification
    • Debt Management Services Providers
    • Health Club Bonds
    • Repossessors
    • Student Loan Servicers: Licensing
    • Telemarketing
  • Recursos en español

Prescription Drug Insulin Pricing Report

The Colorado Department of Law released a report detailing the barriers Coloradans face in receiving the insulin they need and providing recommendations for how to make the vital drug more affordable and accessible.

Insulin prices rose by an inflation-adjusted 262% between 2007 and 2018 in Colorado. As a result, more than 40% of Coloradans who responded to a Department survey said they ration insulin due to cost at least once a year, and, in some cases where individuals lack access to insulin, they even choose to fast as a means of managing their blood sugar levels.

“As captured in this report, the rising price of life-saving insulin has painful consequences for Coloradans and their families,” said Attorney General Phil Weiser. “Our team estimates 73,800 Coloradans rely on insulin to manage their diabetes based on national statistics. Affordable access to insulin and other healthcare is an imperative, and the current COVID-19 pandemic only amplifies this need. It is also clear that we must take the necessary actions so that none of our residents ever has to ration their medication just to survive.”

Read the report here.

Lea el comunicado de prensa sobre el informe de insulina aquí.

Key findings

Key findings in the report include:

  • Costs for Colorado patients more than doubled over seven years.
  • Many Coloradans reported having difficulty accessing supplies as well, such as insulin pumps, which can cost as much as $8,000.
  • Nearly 400 Coloradans from 44 of the state’s 64 counties responded to a survey the Department of Law conducted online in English and Spanish, and many reported struggling with the cost of insulin and other equipment they need.
  • The mental and physical toll for diabetes patients has only increased as the COVID-19 pandemic has continued. Survey respondents reported job loss, furloughs, and salary reductions due to the pandemic, which have made survival even more difficult.

Recommendations

State and federal policy recommendations in the report include:

  • Assure transparency in insulin pricing: A bill that passed in 2019 requires drug manufacturers or their representatives to disclose the wholesale acquisition cost of a drug when engaging in marketing activities with health care providers and other prescribers. While this bill was an important step, the report recommends more comprehensive, transactional price transparency reporting to the Division of Insurance from each link in the pharmaceutical supply chain, including manufacturers, PBMs, insurance carriers, and wholesalers.
  • Expand mandatory coverage for diabetes supplies: Colorado should pursue additional study regarding cost and availability of diabetes supplies that are processed through insurance and should consider mandating coverage and capping copayments or coinsurance for such supplies.
  • Join a bulk purchasing plan to increase purchasing power: Bulk purchasing gives the purchasers greater bargaining power than they would have on their own individually and may be one way for Colorado to reduce insulin costs. Many states have chosen this option, either beginning their own or joining multi-state pools.
  • Change patent laws: Changing patent laws will allow for easier introduction of generic or biosimilar versions of insulin and will also stimulate greater competition amongst insulin manufacturers.
  • Change drug purchasing laws at the federal level: Permit purchasing outside of the United States, which has higher prices than elsewhere in the developed world, as a strategy for providing access to lower cost supplies of insulin.

HB19-1216

Click here to read HB19-1216.

Act summary:

Effective January 1, 2020, the Act caps the cost sharing a covered person is required to pay for prescription insulin drugs at $100 per 30-day supply of insulin.

The law requires the Department of Law to investigate the pricing of prescription insulin drugs and submit a report of its findings to the governor, the commissioner of insurance, and the Judiciary Committees of the Colorado General Assembly.

$26,054 is appropriated to the Department of Regulatory Agencies for use by the Division of Insurance to implement the act.

Expert partnerships and organizations

These expert organizations assisted in developing the Department of Law's insulin survey:

  • Colorado Department of Public Health and Environment (CDPHE)
  • Colorado Department of Health Care Policy and Financing (HCPF)
  • Rocky Mountain Area of the American Diabetes Association
  • Barbara Davis Center for Diabetes at the CU School of Medicine
  • Rocky Mountain Chapter of the Juvenile Diabetes Research Foundation
  • CU Diabetes and Endocrinology Clinical Trial Program, University of Colorado, Denver VA Medical Center, Division of Endocrinology, Metabolism & Diabetes
  • T1International
  • Rocky Mountain Association of Diabetes Educators

 

Share your experiences

This survey is anonymous, the Department of Law does not intend to receive any personal identifying information via this survey, Google Forms will not send Department of Law personal identifying information unless you include this information in your responses. The Department of Law will keep all information submitted confidential.

Take the survey →

Esta encuesta es anónima, el departamento jurídico no tratara de recibir información personal que identifique a las personas llenando la encuesta, los formularios de Google no mandara información que te identifique al menos que tu incluyas la información en tus respuestas. El departamento jurídico mantendrá toda la información confidencial.

Completa la encuesta →

Office of the Attorney General
Colorado Department of Law
Ralph L. Carr Judicial Building
1300 Broadway, 10th Floor
Denver, CO 80203

(720) 508-6000

Contact the Office of the Attorney General

Contact

Facebook
Twitter
CORONAVIRUS ALERTS